DuRoss Amy 4
4 · BIOLIFE SOLUTIONS INC · Filed Mar 20, 2025
Insider Transaction Report
Form 4
DuRoss Amy
Director
Transactions
- Sale
Common Stock
2025-03-14$24.96/sh−5,632$140,575→ 23,811 total - Award
Common Stock
2025-03-18+6,876→ 30,687 total
Footnotes (3)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-13-2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.18 to $25.91, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.